04 Aug Takenaka Partners Advises Asahi Intecc USA, Inc. on its Acquisition of Rev. 1 Engineering, Inc.

Asahi Intecc USA, Inc. (“Asahi”), a wholly-owned subsidiary of Asahi Intecc Co., Ltd. (“Asahi Group”), has acquired Rev. 1 Engineering, Inc. (“Rev. 1”), a leading provider of outsourced medical device design and engineering services with an emphasis on “First in Kind” design for inventors, start-ups, and top tier original equipment manufacturers (“OEMs”) with particular focus on coronary, vascular, and other related markets. Takenaka Partners LLC (Los Angeles, CA) acted as the financial advisor to Asahi, providing valuation, due diligence, and business advisory services.

Asahi Group, based in Aichi, Japan, primarily develops, produces, and sells guide wires, guiding catheters and balloon catheters which are medical devices indispensable for catheter treatment.  The  company has also expanded its product line to encompass other areas, such as peripheral vascular, abdominal, and cerebrovascular areas.  Asahi Group’s sales channels extend to approximately 110 countries and regions with a market share of approximately 80% in Japan, 30% in the United States, 50% in Europe and the Near and Middle East, and 60% in China. Asahi Group has production sites in Thailand, Vietnam, and the Philippines, and R&D centers in Japan and the United States.

Rev. 1, based in Murrieta, California, was established in 2009 by former engineers from major medical device manufacturers. The company specializes in the design and development of complex, minimally invasive, interventional medical devices and has delivered first-of-kind medical devices for interventional cardiology, structural heart, neuromodulation and drug/device/biologic combination products. Rev. 1’s experience covers a wide range of industry sub-segments and device categories including electroporation, ablation, mapping, drug/device combination products, structural heart/TAVR delivery systems, diagnostic and interventional catheters, balloons and stent delivery and anchoring systems, gene therapy delivery, wound closure and more. In addition to product design work, Rev. 1 also offers testing and regulatory clinical support, prototyping, fabrication and assembly; process improvement and engineering; transfer work to contract manufacturers; and design for manufacturing services.

With the acquisition of Rev. 1, Asahi Group will be able to expand its OEM business in the United States and incorporate Rev. 1’s wide range of product design and development know-how, particularly with regards to cutting-edge catheter development. In exchange, Rev. 1 will be able to utilize Asahi Group’s manufacturing bases to expand existing business from design and development contracts to manufacturing. Through this partnership, both companies will be able to help spread minimally invasive treatment products in a wide range of fields to improve patient quality of life.